Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.71 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.71 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.67 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.67 |
| ▸ | KCNN1 | Q92952 | 2/20 | 0.65 |
| ▸ | KCNN2 | Q9H2S1 | 2/20 | 0.65 |
| ▸ | KCNN3 | Q9UGI6 | 2/20 | 0.65 |
| ▸ | MBD2 | Q9UBB5 | 2/20 | 0.64 |
| ▸ | MECP2 | P51608 | 1/20 | 0.64 |
| ▸ | KDM4A | O75164 | 3/20 | 0.61 |
| ▸ | KDM4B | O94953 | 2/20 | 0.61 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.61 |
| ▸ | KDM5C | P41229 | 2/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.57 |
| ▸ | PPP1CA | P62136 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29078754 | 0.99 | CSNK2A2 (0.73) | CSNK2A2CSNK2BSLC2A1CSNK2A1KCNN1 | |
| SCHEMBL29601353 | 0.99 | CSNK2A2 (0.73) | CSNK2A2CSNK2BSLC2A1CSNK2A1KCNN1 | |
| SCHEMBL24358066 | 0.88 | KCNN1 (0.65) | CSNK2A2CSNK2BSLC2A1CSNK2A1KCNN1 | |
| SCHEMBL30518671 | 0.88 | KCNN1 (0.65) | CSNK2A2CSNK2BSLC2A1CSNK2A1KCNN1 | |
| SCHEMBL24358259 | 0.85 | KCNN1 (0.58) | CSNK2A2CSNK2BSLC2A1CSNK2A1KCNN1 | |
| SCHEMBL30745673 | 0.85 | KCNN1 (0.58) | CSNK2A2CSNK2BSLC2A1CSNK2A1KCNN1 | |
| SCHEMBL24358136 | 0.84 | KCNN1 (0.64) | CSNK2A2CSNK2BSLC2A1CSNK2A1KCNN1 | |
| SCHEMBL29601651 | 0.84 | KCNN1 (0.64) | CSNK2A2CSNK2BSLC2A1CSNK2A1KCNN1 | |
| SCHEMBL27039795 | 0.84 | KCNN1 (0.62) | CSNK2A2CSNK2BSLC2A1CSNK2A1KCNN1 | |
| SCHEMBL24358274 | 0.83 | KCNN1 (0.56) | CSNK2A2CSNK2BSLC2A1CSNK2A1KCNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025891-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CELGENE CORPORATION | 2024-01-25 | — | — | US | disclosed |
| EP-4232449-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | Celgene Corporation (US) | 2023-08-30 | — | — | EP | disclosed |
| CN-116547282-A | Heterocyclic compounds and their use for the treatment of helminth infections and diseases | 新基公司 | 2023-08-04 | — | — | CN | disclosed |
| WO-2022087326-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CELGENE CORPORATION (US) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025891-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CYP8B1, PAH, INHA | CSNK2A2 2270/4885CSNK2B 1709/4885SLC2A1 3987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.